Professional Documents
Culture Documents
HPV report for Ughelli North
HPV report for Ughelli North
REPORT
ON
IN
BY
AYONORITSE TORITSEMOSE
STATE TECHNICAL FACITATOR
i
LGA TEAM
DR OWHOJEDO HENRY - ES
ii
ABBREVIATIONS
1. STI - Sexually Transmitted Infection
2. TD - Tetanus-Diphtheria
4. TM - Trademark
5. TV - Television
20. IV - Intravenous
iii
22. LIO - Local Immunisation Officer
iv
45. SIA - Supplemental Immunisation Activities
v
68. HF - Health Facility
vi
ACKNOWLEDGEMENT
I, Emmanuel Bomo Peters, State Technical Facilitator (STF), hereby express my
heartfelt gratitude to:
- Almighty God for His love, mercies, and undeserved favor upon my life and
throughout the program.
- The National Primary Health Care Development Agency (NPHCDA) under the
leadership of the Federal Ministry of Health (FMOH) for their tireless efforts in
promoting health through immunization and don
- Partner agencies, including WHO and UNICEF, for their invaluable support.
- The Chairman, Ughelli North L.G.A, the LGA Team, and all Health Staff of
Ughelli North L.G.A for their significant contributions to the successful HPV
Intensification in Ughelli North, where I had the privilege of working on the
HPV program.
I am deeply grateful for the collective efforts and support that made this
program a success.
vii
EXECUTIVE SUMMARY
Nigeria is introducing the HPV vaccine into its routine immunization schedule
to complement existing strategies for cervical cancer prevention and control.
The vaccine protects against HPV types 16 and 18, and provides cross-
protection for other types. The World Health Organization (WHO) recommends
HPV vaccination as part of a comprehensive approach to prevent cervical
cancer. Nigeria aims to meet the global target of 90-70-90 by 2030, which
includes 90% of girls fully vaccinated with HPV vaccine by age 15, 70% of
women screened for cervical cancer by age 35 and 45, and 90% of women with
cervical cancer or precancerous lesions treated. The introduction of the HPV
vaccine will be done in phases, starting with 15 states and the Federal Capital
Territory in 2023, followed by 21 states in 2024. The vaccine has undergone
rigorous testing and clinical trials, and has been prequalified by WHO. Nigeria's
introduction of the HPV vaccine aligns with the global strategy to eliminate
cervical cancer as a public health problem.
viii
ix